In meta-analysis by Zhong et al. [32], based on 13 studies with 10 016 women with breast cancer, concerning breast cancer survival, the BRCA1 mutation carriers had worse OS than noncarriers (HR = 1.5, p=0.009) but were not significantly different from noncarriers in terms of progression-free survival (HR = 1.35, p=0.09). This evidence concerns the gene BRCA1 and breast carcinoma.